HOUSTON, Texas — Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells (also referred to as Multi-Antigen Recognizing T cells, or MAR-T cells, by Marker), a technology developed at Baylor College of Medicine for the treatment of hematologic and...
research News
Houston, Texas – Triple-negative breast cancer (TNBC) is the subtype of breast cancer that is the hardest to treat. TNBC patients account for more than 20,000 cases of this condition annually in the U.S. alone. They experience worse outcomes than patients with other breast cancer subtypes – their five-year mortality...
Houston, TX – Hepatoblastoma (HB) is the most common liver cancer in children. Researchers and physicians in the field are concerned because in the last decade HB has been rising rapidly worldwide and has seen the most rapid increase among all pediatric solid tumors. A team led by researchers at...
HOUSTON, TX – Researchers at Baylor College of Medicine and collaborating institutions have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings, published in Nature Cell Biology, show two distinct patterns of B cell abnormalities that could serve...
BUFFALO, NY- January 31, 2024 – A new research paper was published in Oncotarget’s Volume 15, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.” Oligodendrocyte precursor markers have become of great interest to identify new diagnostic and therapeutic targets for diffuse gliomas, since state-of-the-art studies point towards immature...
Braunschweig, Germany – A new research paper was published in Oncotarget’s Volume 14 on December 1, 2023, entitled, “Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.” In multiple myeloma patients, high levels of soluble B-cell maturation antigen (sBCMA) can limit...
Best-corrected visual acuity (BCVA) changes and ocular symptoms may affect the management of belantamab mafodotin (belamaf) dosing among patients with relapsed or refractory multiple myeloma (RRMM), according to research presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Investigators conducted a post hoc investigation from the DREAMM-2 trial (ClinicalTrials.gov...
SHANGHAI, China — Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independently developed and produced by Belief BioMed. BBM-H803 is Belief BioMed’s first gene...
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong clinical activity in patients with renal cell carcinomas (RCC) and non-renal cell carcinoma neoplasms associated with von Hippel-Lindau (VHL)...
BERGEN, Norway — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that a poster presentation detailing additional data from a Phase II trial of bemcentinib in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in second line Non-Small Cell...